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Abstract
Objective: We examined physician perception of blood pressure control and treatment behavior in patients with previous
cardiovascular disease and uncontrolled hypertension as defined by European Guidelines.
Methods: A cross-sectional study was conducted in which 321 primary care physicians throughout Spain consecutively
studied 1,614 patients aged $18 years who had been diagnosed and treated for hypertension (blood pressure $140/90
mmHg), and had suffered a documented cardiovascular event. The mean value of three blood pressure measurements
taken using standardized procedures was used for statistical analysis.
Results: Mean blood pressure was 143.4/84.9 mmHg, and only 11.6% of these cardiovascular patients were controlled
according to 2007 European Guidelines for Hypertension Management target of ,130/80 mmHg. In 702 (49.2%) of the
1426 uncontrolled patients, antihypertensive medication was not changed, and in 480 (68.4%) of these cases this was due
to the physicians judgment that blood pressure was adequately controlled. In 320 (66.7%) of the latter patients, blood
pressure was 130–139/80–89 mmHg. Blood pressure level was the main factor associated (inversely) with no change in
treatment due to physician perception of adequate control, irrespective of sociodemographic and clinical factors.
Conclusions: Physicians do not change antihypertensive treatment in many uncontrolled cardiovascular patients because
they considered it unnecessary, especially when the BP values are only slightly above the guideline target. It is possible that
the guidelines may be correct, but there is also the possibility that the care by the physicians is appropriate since BP ,130/
80 mmHg is hard to achieve, and recent reviews suggest there is insufficient evidence to support such a low BP target.
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Introduction
The patient with cardiovascular disease (CVD) is the most
important priority for cardiovascular prevention in clinical
practice [1,2]. Hypertension (HT) is one of the main prognostic
factors for CVD [1,3], but blood pressure (BP) control in
hypertensive patients with CVD is suboptimal [4,5]. Failure of
the physician to begin or intensify treatment when the therapeutic
goals are not met is a current challenge for research and action
according to some authors [6–8].
Uncertainty as to whether clinical BP reflects the true value of
BP is one of the main reasons for not intensifying therapy in
uncontrolled hypertensive patients, an issue that has been
systematically examined in diabetics with HT [9]. Other studies
have found that one reason physicians say they theoretically would
not intensify treatment [10,11], or actually do not intensify it in
their own practice [10,12,13], is satisfaction with BP values close to
the therapeutic goal. In reality, physicians usually overestimate the
degree of BP control in their patients [14–16]. Other studies have
reported that BP levels at the office visit predict antihypertensive
medication change [9,17–19]. But little is known about the factors
independently associated with overestimation of BP control, and
lack of change in treatment due specifically to that overestimation.
So-called competing demands, estimated by length of the office
visit or number of problems the patient has, may also be factors
that contribute to treatment change for elevated BP [9], or may be
alternatives to the conventional reasons for failing to intensify
treatment [20].
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BP control [7,16,21] suggests that physicians must sometimes have
good reasons for not changing treatment, although few studies
have addressed this question. It has been reported that ‘‘white
coat’’ HT and treatment non-compliance are factors often cited by
physicians as contributors to therapeutic inaction in hypothetical
patients with elevated BP [22], which could be considered inaction
that is clinically appropriate.
For these reasons, the present study examines the clinician
perception of BP control and the physician treatment behavior
(change or no change in antihypertensive medication) in patients
with uncontrolled hypertension. We also examine the main
sociodemographic and clinical factors independently associated
with these, considering some competing demands as an additional
factor. Our study focuses specifically, for the first time, on patients
with previous CVD, in whom clinical inaction could have more
serious consequences, in the primary care setting, where most
hypertensive patients are monitored. The results of this study may
provide useful information to improve the quality of care of
patients with hypertension.
Methods
Ethics statement
The study protocol was approved by the Clinical Research
Ethics Committee of the ‘‘La Paz’’ University Hospital in Madrid.
All the patients provided written informed consent for the study.
Research design and methods
The data are taken from a cross-sectional study conducted
throughout Spain between April and June 2008. A total of 321
primary care physicians from primary healthcare clinics spread
across the geographic regions covered by Spain’s national
healthcare system participated in the study (participation rate,
94.1%). Physicians were chosen in proportion to the number of
inhabitants in each geographic region; and within each region,
selection of physicians also took into account their geographic
dispersion in outpatient practice lists. Physicians mean age of
5167 years, most with over 10 years professional experience and
with morning office hours. These physicians consecutively
recruited 1,812 patients (maximum of 6 patients per physician)
aged 18 years or over, diagnosed with hypertension (BP $140/
901mmHg) and on anti-hypertensive drug treatment for at least
one year, who had suffered at least one of the following
cardiovascular events, documented by hospital medical report:
ischemic stroke (transient ischemic attack or acute stroke); cerebral
hemorrhage; angina or myocardial infarction; coronary revascu-
larization (by-pass, stent); congestive heart failure; or aortofemoral
bypass graft surgery [2,23]. The sample size was predetermined
according to the expected frequency of treatment inaction in HT
in Spain [16].
A specific case report form was filled out by participating
physicians (mostly at the end of the study visit), which included
information on their own practice, data to be obtained from the
patients, information to be drawn from the medical records, and
measurements performed on patients during the study visit.
Structured information was collected on the following cardiovas-
cular risk factors: current smoking (daily cigarette consumption at
least during the last month), dyslipidemia and diabetes mellitus
(type 1 or type 2) recorded in the medical record, obesity (body
mass index (BMI) based on measured height and weight $30 kg/
m
2), and abdominal obesity (measured waist circumference
.102 cm in men and .88 cm in women). Information was also
collected from the medical record on target organ damage: left
ventricular hypertrophy (Sokolow electrocardiographic criteria:
SV1 + RV5–6 .38 mm, or Cornell electrocardiographic criteria:
SV3 + RaVL .28 mm in men and .20 mm in women, or
Cornell product .2440 mm/ms, or echocardiogram with left
ventricular mass index $125 g/m
2 in men, or $110 g/m
2 in
women), arterial wall thickening (in carotid: .0.9 mm or
atherosclerotic plaque), slight increase in serum creatinine (men:
1.3–1.5 mg/dl; women: 1.2–1.4 mg/dl), and microalbuminuria
(30–300 mg/24h, or albumin/creatinine ratio .22 mg/dl in men
and .31 mg/dl in women). Family history of early CVD was also
collected [2,23].
Information on BP and HT was extracted by participating
physicians from the medical record: duration, grade of HT at the
visit before the study visit (previous HT) [23], and current type of
drug treatment (as well treatments related to diet and lifestyle) and
their duration. Treatment compliance was estimated by asking the
patient: ‘‘Most hypertensive patients with complications, like you,
take so many medications that they often dont take some of their
pills. Does this happen to you too?’’
BP was measured three times during the study visit, at rest,
using calibrated mercury sphygmomanometers or validated
automatic devices with appropriate cuff size (two sizes), following
standardized procedures [23]. The mean of these three measure-
ments was used for the statistical analyses, and controlled HT was
defined as BP ,130/80 mmHg, which was the therapeutic target
in individuals with CVD at the time of the survey [2,23].
After measuring BP, physicians filled out a questionnaire asking
a closed-ended question to report if they considered that their
patients’ BP was adequately controlled and if they changed the
antihypertensive drug treatment at the study visit. If they modified
the treatment, they were asked what change had been introduced
(increased dosage, added new drug, drug switch, other) and why
(lack of drug efficacy, side effects, price, other reasons). Treatment
inaction could be defined as no change in treatment despite
uncontrolled BP, although this does not necessarily presuppose an
inappropriate clinician decision. The information on the lack of
change in the treatment was obtained by comparing current
treatment as recorded in the medical history and potential change
in treatment noted at the visit, and the reasons were ascertained,
including the physician’s judgment that the patient did not need a
change in treatment, postponement of the treatment decision by
scheduling the patient for another appointment within 2–3 weeks,
referral to the specialist, patient refusal to accept the change, and
any other reasons the physician wished to note. Sociodemographic
data were also collected on the physicians, as well as number of
patients seen per day, length of patient visit, and whether they
followed guidelines for management of HT.
Statistical analysis
Complete information on all the study variables used was
available for 1,614 patients. The descriptive results are expressed
as absolute frequencies and percentages for the qualitative
variables, and as means with their standard deviations for the
quantitative ones. The rates of BP control and of treatment change
were calculated. We then examined the sociodemographic and
clinical characteristics associated with physician perception of
adequate BP control, and with treatment change, in uncontrolled
hypertensive patients.
Multiple logistic regression models were used to determine
whether the following variables were independently associated
with the main two reasons of ‘‘no treatment change’’ in
uncontrolled hypertensive patients (physician opinion of adequate
control, and early scheduling of next appointment): patient age (in
years), sex, educational level (no education or primary education;
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as obesity (yes/no), abdominal obesity (yes/no), smoking (yes/no),
dyslipidemia (yes/no), diabetes (yes/no), family history of prema-
ture CVD (yes/no), current BP at the office visit ($160/100; 140–
159/90–99; 130–139/80–89 mmHg), previous HT (grade 1 or
140–159/90–99 mmHg; grade 2/3 or $160/100 mmHg), dura-
tion of HT (years), duration of antihypertensive treatment (years),
target organ damage (yes/no), treatment compliance (yes/no),
mean number of patients/day, mean consultation time per patient
(minutes), and physician compliance with guidelines for HT
management. Following the bivariate analyses, criteria of clinical
relevance (variables shown to be clinically relevant in the
literature) and of statistical significance (bivariate p,0.20) were
used to select the variables for the multiple logistic regression.
Statistical significance was established at p,0.05 for 2-tailed tests.
The analysis was made with SPSS package version 15.0 (SPSS,
Chicago, IL, USA).
Results
Mean patient age was 66.5 (610.8) years, 62,6% were men, and
27.8% had secondary or higher level education (Table 1). Some
39.3% were obese, 64% had abdominal obesity, and 34.4% had
diabetes (type 2 in 95% of cases). Half of the patients had target
organ damage. Mean duration of HT (from time of diagnosis) was
9.2 years, and mean duration of antihypertensive treatment was 8
years. In the visit before the study visit (95% had visited in the
previous three months), 55.3% had grade 1 HT.
All patients were currently being treated with at least one
antihypertensive drug: 24.9% in monotherapy, 42.8% with two
drugs, and 32.3% with three or more drugs (p,0.001). In all,
58.5% of patients said they were complying with their drug
treatment. In addition, a low salt diet had been recommended to
82% of patients, and a low calorie diet to 65.2%.
The participating physicians saw a mean of 46.7618.6 patients
per day, with an average visit time of 7.362.9 minutes. About
83% stated that they used guidelines for HT management.
Blood pressure control and physician perception of
control
Mean BP at the study visit (current BP) was 143.4 (616.1)/84.9
(611.2) mmHg (Table 1). About 69.6% of the 1,426 uncontrolled
patients had levels $140/90 mmHg, and 30.4% had 130–139/
80–89 mmHg (Table 2). Control varied from 7.9% in patients
with heart failure to 15.6% in those with ischemic heart disease,
with better control of diastolic than systolic BP.
BP control according to the physician (subjective control)
after evaluating the values measured in the visit was 46.8%
(95% CI. 43.2%–50.4%), much higher than the 11.6% of
control (95% CI, 7.0%–16.2%) observed when the objective
measure was used (Table 2). The degree of physician
overestimation of objective BP control clearly decreases with
increasing threshold for BP control: 35.3% of all hypertensive
patients (or 40% of uncontrolled hypertensive patients) if $130/
80 mmHg, 10.9% if $140/90 mmHg, and 1.2% if $160/
100 mmHg (Table 2).
In multivariate analysis, overestimation of control was less likely
in patients with higher BP levels above goal (Table 3). In addition,
abdominal obesity, target organ damage and non-compliance with
treatment were associated with less overestimation. The rest of the
statistically significant variables in the bivariate analysis (previous
HT, smoking and dyslipidemia) lost significance in the multivariate
analysis.
Physician treatment behavior
Physicians maintained the dietary treatment in almost 90% of
patients at the visit. The drug regimen was modified in 724
(50.8%) patients with uncontrolled hypertension (Table 4), in
most cases (90%) by adding a new drug or increasing the dose.
Drug treatment was not modified in 702 uncontrolled hyperten-
sive patients (49.2%).
In the 570 uncontrolled hypertensive patients perceived to be
controlled (Table 2), the most frequent physician behavior was lack
of change in treatment (in 480 patients) due to the belief that the
patient did not require a change in treatment (Table 4). This
represented 68.4% of all cases of treatment inaction. Treatment was
changed in only 90 patients for different reasons. In the 856
hypertensive patients correctly perceived to be uncontrolled
(Table 2), the predominant physician behavior was change in
treatment (634 patients), in almost all cases (615) because the drug
was not considered to be effective (Table 4). In the 222 remaining
patients correctly classified as uncontrolled, the physicians made no
Table 1. Sociodemographic and clinical characteristics of the
study sample.
Variable
Age, years (SD) 66.5 (610.8)
Men, % 62.6
Educational level, %
No education or primary level 72.2
Secondary level or university 27.8
Systolic/diastolic blood pressure at office visit,
mmHg (SD)
143.4 (616.1) / 84.9
(611.2)
Systolic/diastolic blood pressure ,130/80 mmHg, % 11.6
Previous hypertension grade, %
Grade 1 (140–159/90–99 mmHg) 55.3
Grade 2/3 ($160/100 mmHg) 44.7
Body mass index, kg/m
2 29.4 (64.9)
Waist circumference, cm 101.7 (615.3)
Obesity, % 39.3
Abdominal obesity, % 64.0
Smoking, % 23.3
Dyslipidemia, % 67.4
Diabetes mellitus, % 34.4
Family history of early CVD, % 43.3
Compliance with drug treatment, % 58.5
Target organ damage, % 53.2
Left ventricular hypertrophy 38.9
Arterial wall thickening 23.0
Mild increase in serum creatinine 25.2
Microalbuminuria 20.4
Associated cardiovascular disease, % 100.0
Ischemic heart disease or coronary
revascularization
68.4
Cerebrovascular disease 23.7
Heart failure 17.6
Peripheral artery disease 13.3
CVD indicates cardiovascular disease. See Methods section for definition of risk
factors.
doi:10.1371/journal.pone.0024569.t001
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for another appointment at an early date (within 2–3 weeks)
(Table 4).
Reasons and determinants for lack of change in
treatment. Adequate BP control and early next
appointment
The frequency of not changing treatment due to physician belief
that patients were controlled was moderate (160 cases or 33.3%) in
hypertensive patients with elevated current BP at visit ($140/
90 mmHg), and very low (3.9%) if BP was very high ($160/
100 mmHg) (Table 5). However, the proportion was considerable
(320 cases or 66.7%) when current BP was only mildly elevated
(130–139/80–89 mmHg), especially if previous HT was grade 1.
In all, these 320 cases account for 45.6% of all cases of treatment
inaction. Lack of change in treatment due to scheduling the next
appointment within 2–3 weeks was also higher when current BP
was marginally or moderately elevated (74.4%) than when it was
frankly elevated ($160/100 mmHg) (25.6%) (Table 5).
Table 6 s h o w so n l yt h o s ev a r i a b l e st h a tr e m a i n e ds t a t i s t i c a l l y
significant in the multivariate analysis.Current BP was the factor with
the strongest independent association with lack of treatment change
due to physician perception of adequate BP control. Compared to
patients with BP 130–139/80–89 mmHg at the visit, treatment
inaction was less likely in those with BP 140–159/90–99 mmHg
(OR, 0.11; 95% CI 0.08 to 0.15), and much less likely in patients with
more elevated BP ($160/100 mmHg) (Table 6). The frequency of
treatment inaction was also lower in patients with abdominal obesity,
with target organ damage, or in non-compliant patients, irrespective
of current BP levels. Previous grade of HT and other variables
significantly associated with treatment inaction in the bivariate
analysis, lost significance in the multivariate analysis. Finally, in the
multivariate analysis, the frequency of not changing treatment due to
early next appointment (in 2–3 weeks) was highest in patients with
abdominal obesity or target organ damage.
Discussion
Physicians overestimate the level of BP control in hypertensive
patients: 40% of patients who in reality have uncontrolled
hypertension are perceived as being adequately controlled. The
difference between objective BP control and control as perceived
by physicians has also been observed in other studies [14–16,24].
Furthermore, the magnitude of treatment inaction in our study
was almost 50%, similar to that reported in other studies in
primary care [24], and lower than that observed in some other
studies [7,16], including those found in cardiovascular patients in
specialty care [21]. However, the prevalence of inaction varies
depending on the different methodologies and populations in the
various studies [7,9–13,16–18,21,24,25]. Interestingly, factors
predictive of overestimation of control and of lack of change in
treatment due to misperception of BP control are consistent. In
patients who have more elevated BP levels, are obese, or do not
comply with treatment – that is, those with higher cardiovascular
risk – physicians tend to be less permissive; in these cases
physicians are less likely to overestimate the level of control and
are more likely to treat more intensely.
Reasons for not changing treatment
The lack of change in treatment by physicians in uncontrolled
hypertensive patients does not appear to be primarily a problem of
Table 2. Blood pressure control based on measurement
(objective) and according to physician opinion (subjective).
Objective control
Subjective
control ,130/80 mmHg $130/80 mmHg Total
Yes 185 (11.5%) 570 (35.3%) 755 (46.8%)
No 3 (0.2%) 856 (53.0%) 859 (53.2%)
Total 188 (11.6%) 1426 (88.4%) 1614 (100%)
,140/90 mmHg $140/90 mmHg Total
Yes 579 (35.9%) 176 (10.9%) 755 (46.8%)
No 43 (2.7%) 816 (50.6%) 859 (53.2%)
Total 622 (38.5%) 992 (61.5%) 1614 (100%)
,160/100 mmHg $160/100 mmHg Total
Yes 735 (45.5%) 20 (1.2%) 755 (46.8%)
No 559 (34.6%) 300 (18.6%) 859 (53.2%)
Total 1294 (80.2%) 320 (19.8%) 1614 (100%)
doi:10.1371/journal.pone.0024569.t002
Table 3. Patient factors associated with physician
overestimation of blood pressure control in uncontrolled
hypertensive patients, from multivariate logistic analysis.
Patient factor Odds Ratio (95% CI) P
Blood pressure at the study visit
140–159/90–99 vs. 130–139/80–
89 mmHg
0.04 (0.02–0.06) ,0.001
$160/100 vs. 130–139/80–89 mmHg 0.007 (0.003–0.013) ,0.001
Abdominal obesity (yes vs. no) 0.71 (0.51–0.97) 0.035
Target organ damage (yes vs. no) 0.74 (0.55–1.00) 0.050
Treatment compliance (no vs. yes) 0.60 (0.44–0.82) 0.002
doi:10.1371/journal.pone.0024569.t003
Table 4. Physician treatment behavior in uncontrolled
hypertensive patients, and its causes.
Therapeutic behavior N (%)
Total 1426
Change in drug treatment 724 (50.8%)
Lack of efficacy 615 (85%)
Intolerance/adverse effects 22 (3%)
Price 3 (0.4%)
Other 84 (11.6%)
No change in drug treatment 702 (49.2%)
Not necessary (adequate control) 480 (68.4%)
Early appointment scheduled 176 (25.1%)
Referral to specialist 12 (1.7%)
Patient does not accept change 11 (1.6%)
Other 23 (3.2%)
Uncontrolled hypertension: current blood pressure $130/80 mmHg.
Adequate control: Physician deems control to be adequate (after examining
patient’s current blood pressure values).
Early appointment scheduled: Patient scheduled for appointment within 2–3
weeks.
doi:10.1371/journal.pone.0024569.t004
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stated that they knew them. In fact, physicians were informed in
the study protocol about the appropriate BP target in high-risk
patients at work at the time of the survey (,130/80 mmHg; 2007
European guidelines) [2,23]. However, physicians did not
implement the guidelines with respect to this ‘‘demanding’’
treatment targets in cardiovascular patients. BP control achieved
under this target was very low, physicians made changes in
treatment in only a half of uncontrolled hypertensive patients, and
lack of treatment changes occurred in those at only moderately
elevated BP values.
Several reasons may explain these findings. First, physicians
may be uncertain about the levels of clinical BP, especially when
they are only slightly elevated [9,19]. In our study, a substantial
proportion of cases of absence of treatment change in uncontrolled
hypertensive patients occurred when BP values were 130–139/80–
89 mmHg, near the therapeutic target in patients with previous
CVD (,130/80 mmHg). Also, the physicians who chose to have
the patient return in 2 to 3 weeks were possibly taking the most
appropriate action as they were most likely aware of the
inaccuracy and variability of BP measurements. In fact, physicians
lack of treatment change due to appointment in 2–3 weeks was
more frequent when patients had slightly elevated current BP than
when they had frankly elevated current BP levels.
Second, it must be considered that a guideline-based low BP
goal in CVD patients (say ,130/80 mmHg) is not consistently
supported by trial evidence, as shown after performance of this
survey [26,27]. Thus, many physicians may be sceptical of
guidelines as they are frequently based primarily on expert
opinion and subject to bias and conflicts of interest. Likewise, our
results also suggest that many physicians consider that small
elevations of visit BP levels above goal are not of concern and pose
little risk to patient health. In fact, the trial-based differences in
achieved cardiovascular protection within this range of BP values
seem to be small at best [27]. BP levels much higher than the
target, however, are associated with increased clinical action.
Third, BP control under 130/80 mmHg is possibly difficult to
achieve in many patients. In major trials it has been shown that a
target of ,140/90 mmHg is only achieved in approximately 60%
of patients despite use of 3 or more drugs [28]. In fact, we obtained
a quite low (11.6%) rate of BP control in CVD patients under the
stringent target ,130/80. This makes the concept of putting
blame on the physicians inappropriate.
Fourth, of 702 uncontrolled patients in whom physicians did not
change treatment, 216 (30.8%) were receiving three or more
antihypertensive drugs. In most of these cases, patients were
considered by physicians at adequate BP control or had an early
next appointment. Although we did not directly ask for number of
drugs prescribed as a potential reason for not changing therapy, it
could be suggested that it was an additional reason. Fifth, inaction
is not explained by physicians having taken additional non-drug
measures because in most patients they continue the same dietary
and lifestyle recommendations as before the visit. However,
treatment compliance does affect inaction, since physicians were
Table 5. Frequency of main reasons for lack of change in antihypertensive treatment, stratified by previous and current blood
pressure values.
Reasons for not changing treatment
Previous hypertension grade and current blood pressure Adequate control Appointment in 2–3 weeks
Previous grade 1 HT and current BP 130–139/80–89 mmHg 229 (47.7%) 30 (17.0%)
Previous grade 2/3 HT and current BP 130–139/80–89 mmHg 91 (19.0%) 19 (10.8%)
Previous grade 1 HT and current BP 140–159/90–99 mmHg 69 (14.4%) 46 (26.1%)
Previous grade 2/3 HT and current BP 140–159/90–99 mmHg 72 (15.0%) 36 (20.5%)
Previous grade 1 HT and current BP $160/100 mmHg 3 (0.6%) 9 (5.1%)
Previous grade 2/3 HT 3 and current BP $160/100 mmHg 16 (3.3%) 36 (20.5%)
Total 480 (100%) 176 (100%)
Not changing treatment: Physician does not change drug treatment in patient with uncontrolled hypertension.
Previous HT: Hypertension grade at visit before the study visit.
Current BP: Blood pressure at the study visit.
doi:10.1371/journal.pone.0024569.t005
Table 6. Factors associated with lack of change in treatment
in uncontrolled hypertensives patients, by the main reasons
asserted by physicians, from multivariate logistic analysis.
Reason for not changing treatment Odds Ratio (95% CI) P
Adequate control
Blood pressure at the study visit
140–159/90–99 vs. 130–139/
80–89 mmHg
0.11 (0.08–0.15) ,0.001
$160/100 vs. 130–139/
80–89 mmHg
0.02 (0.01–0.04) ,0.001
Abdominal obesity (yes vs. no) 0.63 (0.47–0.85) 0.003
Target organ damage (yes vs. no) 0.67 (0.50–0.90) 0.007
Treatment compliance (no vs. yes) 0.65 (0.48–0.87) 0.004
Early appointment scheduled
Blood pressure at the study visit
140–159/90–99 vs. 130–139/
80–89 mmHg
1.11 (1.03–1.13) 0.012
$160/100 vs. 130–139/80–89 mmHg 1.13 (1.12–1.14) 0.015
Abdominal obesity (yes vs. no) 1.25 (1.01–1.50) 0.048
Target organ damage (yes vs. no) 1.46 (1.10–1.93) 0.008
Adequate control indicates that patient does not require change in
antihypertensive medication because physician deems control to be adequate
(after examining patient’s current blood pressure values);
Early appointment scheduled: Physician does not change treatment because
patient scheduled for appointment within 2–3 weeks.
doi:10.1371/journal.pone.0024569.t006
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influence on inaction of competing demands, or problems that
most worry the physician in the visit, has varied in different studies
[9,20]. In our study, neither the length of the visit nor patient
comorbidities (considered indirectly through the number of drugs
taken for other conditions – data not shown), were significantly
associated with inaction in the multivariate analysis.
We are not prejudging what the correct therapeutic decisions
are in any particular case. However, caution is needed if BP levels
are clearly elevated ($140/90 mmHg, and especially if $160/
90 mmHg), which are less consistent with clinical uncertainty and
in which the associated cardiovascular risk is appreciable.
Methodological aspects
The study patients are reasonably representative of the
hypertensive population attended in primary care centers in Spain
[29]. Moreover, the high response rate (89.1%) minimizes
selection bias, and we used specific and detailed information from
physicians, patients, and medical records. There is a predomi-
nance of males, but this reflects what is found in actual clinical
practice with patients with cardiovascular disease. The extent to
which our findings are generalizable to other populations is
uncertain, although overall rates of BP control (,140/90 mmHg)
in our study population were similar to those obtained in studies in
other countries [4,5]. Moreover, these limitations would not
necessarily affect the associations found between treatment change
and its predictive factors.
Furthermore, we decided to categorize patient BP levels, given
the pragmatic clinical definition of HT and its control, that is,
given usual medical behavior in clinical practice.
Patient compliance with therapy, which could explain some
cases of lack of change in treatment, was not considered in detail in
our study. However, some studies have shown that questionnaires
can reasonably identify non-compliant patients [30].
Although obtaining information on therapeutic behavior during
the study visit could increase treatment change, this would result in
an underestimate of the proportion of treatment inaction
observed. Also, although the type of visit in our study was not
specifically for HT monitoring, and this may have somewhat
overestimated treatment inaction, the reason for most patient visits
was monitoring of their HT.
Finally, neither ambulatory nor self-measured data on BP were
available, thus treatment inaction might be partially explained by
physicians belief that actual BP was lower than BP measured at the
office (white-coat effect).
Conclusion
Physicians generally do not comply with BP guidelines
concerning application of very low BP target in CVD patients.
Physicians do not change antihypertensive treatment in many
uncontrolled hypertensive patients because they considered it
unnecessary or because they scheduled an early appointment,
especially when the BP values are only moderately elevated.
Overall, it is possible that the guidelines may be correct, but
there is also the possibility that the care by the physicians is
entirely correct or that the patients who have BPs ,130/
80 mmHg are being overtreated and being put unnecessarily at
risk. In fact, the risk for all-cause death and myocardial infarction
progressively increases with low diastolic BP, and excessive
reduction in diastolic pressure should be avoided in patients with
coronary artery disease who are being treated for hypertension
[31].
New studies are needed on the social and health consequences
of greater BP permissiveness and to clarify the most scientifically
appropriate therapeutic targets that are feasible in medical
practice [26,27]. Our finding of inaction that is probably
appropriate in those with mildly elevated BP levels would be an
additional argument in favor of recent proposals of less stringent
therapeutic targets in high-risk hypertensive patients [26,27].
Finally, additional prospective data (our study was cross-sectional)
are also needed on factors that act as barriers to intensification of
therapy over time.
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